Microwave Ablation versus Stereotactic Body Radiotherapy for Stage I Non–Small Cell Lung Cancer: A Cost-Effectiveness Analysis
- 28 April 2022
- journal article
- research article
- Published by Elsevier in Journal of Vascular and Interventional Radiology
- Vol. 33 (8) , 964-971.e2
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Radiofrequency ablation of stage IA non–small cell lung cancer in medically inoperable patients: Results from the American College of Surgeons Oncology Group Z4033 (Alliance) trialCancer, 2015
- Percutaneous microwave ablation for early‐stage non‐small cell lung cancer (NSCLC) in the elderly: A promising outlookJournal of Medical Imaging and Radiation Oncology, 2014
- Updating Cost-Effectiveness — The Curious Resilience of the $50,000-per-QALY ThresholdNew England Journal of Medicine, 2014
- Percutaneous microwave ablation of stage I medically inoperable non‐small cell lung cancer: Clinical evaluation of 47 casesJournal of Surgical Oncology, 2014
- Cost‐effectiveness of stereotactic body radiation therapy versus surgical resection for stage I non–small cell lung cancerCancer, 2013
- Cost-Effectiveness Analysis of Stereotactic Body Radiotherapy and Radiofrequency Ablation for Medically Inoperable, Early-Stage Non–Small Cell Lung CancerInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2011
- Lung cancer treatment costs, including patient responsibility, by disease stage and treatment modality, 1992 to 2003Value in Health, 2011
- Radiofrequency Ablation versus Nephron-sparing Surgery for Small Unilateral Renal Cell Carcinoma: Cost-effectiveness AnalysisRadiology, 2008
- Pulmonary Radiofrequency Ablation: Long-term Safety and Efficacy in 153 PatientsRadiology, 2007
- Percutaneous Radiofrequency Ablation of Malignancies in the LungAmerican Journal of Roentgenology, 2000